Contact Us
Drug Search Results
More Filters [+]

Ocifisertib

Alternative Names: Ocifisertib, cfi-400945, cfi400945, cfi 400945
Latest Update: 2024-08-22
Latest Update Note: Clinical Trial Update

Product Description

CFI-400945 is an oral (taken by mouth) drug that works by blocking polo-like kinase 4 (PLK4) from working. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01954316)

Mechanisms of Action: PLK4 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Fast Track - Acute Leukemia|Acute Myeloid Leukemia|Leukemia|Myeloid Leukemia *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Treadwell Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ocifisertib

Countries in Clinic: Canada, Hong Kong, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Myelodysplastic Syndrome|Triple Negative Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
TWT-202

P2

Recruiting

Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Myelodysplastic Syndrome|Acute Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Acute Myeloid Leukemia|Acute Monocytic Leukemia

2026-01-01

I239

P2

Active, not recruiting

Triple Negative Breast Cancer

2022-09-15

Recent News Events

Date

Type

Title

04/08/2024

News Article

 ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

02/20/2024

News Article

 Treadwell Announces Ocifisertib, a First-in-Class PLK4 Inhibitor, has Received Orphan Designation from U.S. FDA for the Treatment of Acute Myeloid Leukemia

02/16/2024

PubMed

 PLK4 as a potential target to enhance radiosensitivity in triple-negative breast cancer.

02/05/2024

PubMed

 Therapeutic potential of targeting polo-like kinase 4.

01/01/2024

PubMed

 Seize the engine: Emerging cell cycle targets in breast cancer.

12/15/2023

News Article

 Treadwell Therapeutics Announces a Presentation at the 2023 ASH Annual Meeting and Advisory Board Meeting

12/06/2023

News Article

 Treadwell Announces Strategic Pipeline Prioritization and Leadership Transitions

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions